CA-THE-MOPRIA-ALLIANCE
The Mopria® Alliance , a global non-profit organization providing universal standards and solutions for print and scan, today announced Android 11 includes new print capabilities and enhancements contributed by the Alliance in collaboration with the Google Android team.
A new “Share-to-Print” feature of the Android Default Print Service enables users to print images and documents from thousands of social media and productivity applications directly from their Android device. Practically any Android app that allows users to share files such as JPEG, BMP, PNG, GIF and PDF, now also includes a convenient and simple option to print those items as well.
Additionally, the “Share-to-Print” path for photo printing supports specific enhancements to ensure best fit and higher resolution on the printed page. These enhancements result in high-quality prints, regardless of aspect ratio of the photo or size of the print.
“With this update, we set out to integrate print features that would make the lives of mobile users easier and continue to push the envelope of what we can provide in the Default Print Service,” said Ingrid Kelly, Chairperson of the Board at the Mopria Alliance. “We achieved those goals in the Android 11 update, and we are excited to continue to invest in and demonstrate our commitment to providing an enhanced printing experience for Android users.”
For people wanting to maximize the features available in their printers that may not be supported by the Default Print Service, the update adds on-the-fly selection of other brand-specific print services and the Mopria Print Service . Users are able to select and install these additional print services directly in their print workflow to enable even more print features.
To date, Mopria print technology has been installed on more than 2 billion devices, including Windows PCs and laptops, Android phones and tablets, FireOS tablets and ChromeOS notebooks. Mopria print technology is designed to simplify desktop printing and mobile printing to more than 4,000 printer models and more than 120 million Mopria certified printers .
The Mopria Alliance membership represents many of today’s global printer businesses, OS providers, device manufacturers and software vendors. In addition to the founding companies, Canon, HP, Samsung and Xerox, Mopria Alliance members include Adobe, Brother, EFI, Epson, Fuji Xerox, Huawei, Konica Minolta, Kyocera, Lexmark, Microsoft, OKI Data, Pantum, Primax, Qualcomm, Ricoh, Toshiba, Xiaomi and YSoft.
The new Default Print Service features will be available to Android users who update to Android version 11. For the latest list of Mopria certified printers and print accessories, please visit https://mopria.org/certified-products .
About the Mopria® Alliance
The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the mission of providing universal standards and solutions for print and scan. With a focus on mobility and modern productivity trends, Mopria technology is used to allow users to interact intuitively and seamlessly with a printer, multi-function printer or scanner, regardless of brand. Learn more at www.mopria.org . Print. Scan. Go.
Android is a trademark of Google Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom